论文部分内容阅读
目的:探讨胃泌素释放肽前体(ProGRP)对小细胞肺癌(SCLC)的诊断价值。方法:用ELISA的方法检测SCLC患者血清中ProGRP水平,并与神经元特异性烯醇化酶(NSE)对照,观察ProGRP水平与肿瘤分期和治疗效果的关系。结果:ProGRP诊断SCLC的敏感性为75.5%,特异性为82.6%,ProGRP和NSE联合检测的敏感性为88.9%,特异性为52.2%。广泛期SCLC患者血清ProGRP水平高于局限期患者,二者分别为(515.0±310.6)pg/m l和(158.8±102.5)pg/m l(P=0.0003),其差异具有显著性意义。临床治疗有效的SCLC患者,治疗后ProGRP水平较治疗前明显下降,而治疗无效病例则无下降甚至升高。结论:ProGRP作为SCLC的标志物,具有敏感性高、特异性强的特点,并可准确反映SCLC病情及化疗效果。ProGRP和NSE的联合检测是肺癌分型及SCLC早期诊断的较好指标。
Objective: To investigate the diagnostic value of gastrin-releasing peptide precursor (ProGRP) for small cell lung cancer (SCLC). Methods: The level of ProGRP in sera of SCLC patients was detected by ELISA and compared with neuron specific enolase (NSE) to observe the relationship between ProGRP level and tumor staging and therapeutic effect. Results: The sensitivity and specificity of ProGRP for diagnosis of SCLC were 75.5% and 82.6% respectively. The sensitivity and specificity of ProGRP and NSE were 88.9% and 52.2% respectively. Serum levels of ProGRP in patients with extensive stage SCLC were significantly higher than those in patients with limited stage (515.0 ± 310.6 pg / m l and 158.8 ± 102.5 pg / m l, respectively; P = 0.0003). The clinical treatment of patients with SCLC, ProGRP levels after treatment decreased significantly compared with before treatment, but the treatment of ineffective cases did not decline or even increase. Conclusion: ProGRP, as a marker of SCLC, has the characteristics of high sensitivity and specificity. It can accurately reflect the condition of SCLC and the effect of chemotherapy. ProGRP and NSE combined detection of lung cancer and SCLC early diagnosis of a better indicator.